The Food and Drug Administration has approved a new propylene glycol–free formulation of melphalan hydrochloride as a high-dose conditioning treatment for autologous stem cell transplantation, and as a palliative therapy for multiple myeloma.

Evomela (Spectrum Pharmaceuticals) is intended to be reconstituted with normal saline at the time of intravenous administration. The solution is stable for 4 hours using Captisol, a proprietary agent containing modified cyclodextrin. It is also stable for 1 hour after reconstitution.

Extended stability without the need for propylene glycol is its major advantage over the other formulations of melphalan, a chemotherapy agent originally approved in 1964, according to a statement by Spectrum.

Evomela was approved on the basis of a phase IIa pharmacokinetic trial comprising 24 patients undergoing autologous stem cell transplantation. Evomela was bioequivalent with Alkeran, with a 10% higher maximum plasma concentration and area under the plasma concentration-time curve ( Bone Marrow Transplant. 2014 Aug;49[8]:1042-5 ).

According to that, and other studies, adverse reactions included decreased neutrophil count (100%), decreased white blood cell count (100%), decreased lymphocyte count (98%), decreased platelet count (98%), diarrhea (93%), nausea (90%), fatigue (77%), hypokalemia (74%), anemia (66%), and vomiting (64%). About 2% of patients have experienced hypersensitivity reactions.

For palliative treatment, the recommended does is 16 mg/m2 infused over 15-20 minutes at 2-week intervals for four doses, and then, after adequate recovery from toxicity, at 4-week intervals.

For conditioning treatment, the recommended does is 100 mg/m2 per day infused over 30 minutes for 2 consecutive days before stem cell transplant.


You May Also Like

CSF markers differentiate Parkinson’s, predict related dementia

FROM JAMA NEUROLOGY Certain cerebrospinal fluid biomarkers may help differentiate Parkinson’s disease from other ...

Supreme Court declines to hear DACA case

The U.S. Supreme Court has declined to decide for now whether the Deferred Action ...